杨丽霞,郭瑞威

• 1:解放军昆明总医院心血管内科中国胸痛中心

摘要(Abstract)：

<正>急性冠状动脉综合征(acute coronary syndrome,ACS)是在冠状动脉粥样硬化斑块侵袭或者破裂的前提下,以完全或不完全闭塞性血栓形成为病理基础的一类临床综合征,一般症状是发作性胸闷、胸痛,可迅速进展为恶性心律失常、心力衰竭,甚至猝死,严重威胁患者的生命[1]。随着经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)技术的广泛应用,ACS患者成为此项技术的最大受益人

关键词(KeyWords)： 急性冠状动脉综合征;经皮冠状动脉介入治疗;指南解读

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 杨丽霞,郭瑞威

参考文献(References)：

• [1]方唯一,仇兴标.最新ACC/ESC血小板糖蛋白Ⅱb/Ⅲa抑制剂相关指南解读.中国介入心脏病学杂志,2014,22(12):814-816.
• [2]中华医学会心血管病学分会介入心脏病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南(2016).中华心血管病杂志,2016,44(5):382-400.
• [3]Danchin N,Coste P,Ferrières J,et al.Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction:data from the french registry on acute ST-elevation myocardial infarction(FAST-MI).Circulation,2008,118(3):268-276.
• [4]Armstrong PW,Gershlick AH,Goldstein P,et al.Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.NEngl J Med,2013,368(15):1379-1387.
• [5]Sim DS,Jeong MH,Ahn Y,et al.Manual thrombus aspiration during primary percutaneous coronary intervention:Impact of total ischemic time.J Cardiol,2016,pii:S0914-5087(16)00013-7.
• [6]Toth GG,Kala P,Lansky A,et al.Will this trial change my practice?PRAMI-treatment of bystander coronary lesions in patients undergoing primary PCI for acute STEMI.EuroI ntervention,2014,10(3):411-412.
• [7]Kelion AD,Pakkal MV,Chowdhury FU,et al.Ischemia and Infarction in STEMI Patients With Multivessel Disease:Insights From the CvL PRIT Nuclear Substudy.J Am Coll Cardiol,2016,67(22):2698-2699.
• [8]Engstrm T,Kelbk H,Helqvist S,et al.Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease(DANAMI-3-PRIMULTI):an open-label,randomised controlled trial.Lancet,2015,386(9994):665-671.
• [9]Hlinomaz O.Multivessel coronary disease diagnosed at the time of primary PCI for STEMI:complete revascularization versus conservative strategy.PRAGUE 13 trial[R/OL].2015[2016-03-02.http://sbhci.org.br/wpcontent/uploads/2015/05/PRAGUE-13-Trial.pdf]
• [10]Sarathy K,Nagaraja V,Kapur A,et al.Target-vessel versus multivessel revascularisation in ST-elevation myocardial infarction:a meta-analysis of randomised trials.Heart Lung Circ,2015,24(4):327-334.
• [11]Kelbk H,Hfsten DE,Kber L,et al.Deferred versus conventional stent implantation in patients with ST-segment elevation myocardial infarction(DANAMI 3-DEFER):an openlabel,randomised controlled trial.Lancet,2016,pii:S0140-6736(16)30072-1.
• [12]郭新贵.解读欧美指南---再议新型P2Y12抑制剂治疗地位.中国介入心脏病学杂志,2015,23(1):55-58.
• [13]Shimada YJ,Bansilal S,Wiviott SD,et al.Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes:Analysis from the Platelet Inhibition and Patient Outcomes(PLATO)Trial.Am Heart J,2016,177:1-8.
• [14]Giannitsis E,Wallentin L,James SK,et al.Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation:A Platelet Inhibition and Patient Outcomes(PLATO)trial biomarker substudy.Eur Heart J Acute Cardiovasc Care,2016,pii:2048872616641901.
• [15]Han Y,Guo J,Zheng Y,et al.Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction:the BRIGHTrandomized clinical trial.JAMA,2015,313(13):1336-1346.
• [16]Banach M,Serban MC,Sahebkar A,et al.Comparison of clinical outcomes between bioresorbable vascular stents versus conventional drug-eluting and metallic stents:a systematic review and meta-analysis.EuroI ntervention,2016,12(2):e175-e189.
• [17]张岩,霍勇.推动我国医疗急救体系建设:从急性心肌梗死救治开始.北京大学学报(医学版),2014,46(6):829-831.